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INTRODUCTION
Various therapeutic approaches have been recently
made for atopic dermatitis (AD) because of the
marked increase in the number of patients with
AD and the appearance of numerous severe cases.
Nevertheless, there are many refractory cases in
which sufficient effects have not been obtained.
We developed an ointment containing eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) as a
topical preparation for AD (1). We applied this
ointment to 64 patients with AD who did not show
improvement of symptoms by conventional treat-
ments and obtained satisfactory results.
SUBJECTS
The subjects were 64 patients with AD (infancy
28, early childhood 15, later childhood 10, adolescence
5 and adulthood 6) who were treated topically with
our newly developed EPA/DHA-containing ointment.
The diagnosis of AD was made according to the
Japanese Dermatological Association Criteria (2).
These patients previously showed poor responses
to conventional treatments including dietetics, oral
administration of anti-allergic agents and applica-
tion of topical preparations such as topical steroids
or topical non-steroidal antiinflammatory drugs.
We provided sufficient information concerning the
ointment to all patients and obtained their consent
to participate in the study.
MATERIAL
EPA/DHA containing ointment : EPA and DHA
were extracted and purified from fish oils as a
powdered product (N-Neopowder DHA20, NOF
Co., Ltd.). Although the powder itself was stable
for 8 weeks at room temperature, the patients were
requested to store the ointment at 4℃ and to dis-
card it 4 weeks after preparation because its stabil-
ity had not been fully examined (the product showed
discoloration after several months). This ointment
was prepared so that it contained a hydrophilic
ointment base, 1.2 % DHA and 0.6 % EPA.
METHOD
The patients were basically treated by the EPA/
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DHA-containing ointment alone. Those who had
been given dietetics or oral administration of
anti-allergic agents in other hospitals continued to
these treatments while the drugs for topical use
were replaced by the EPA/DHA-containing ointment.
The ointment was applied to the target lesion 2 or
3 times a day and the effects were evaluated after
4 weeks of treatment. A dermatologist assisted with
the evaluation. Skin symptoms were categorized into
erythema, papule, squama, itching, thickening, crust
and erosion, and the severity of each symptom was
scored as follows : 3 points represented a severe
lesion, 2 points a moderate lesion, 1 point a mild
lesion and 0 point indicated no symptom. Then, the
efficacy was evaluated by an increase or decrease
in the score before and after the treatment. If some
skin symptoms appeared in several sites in the
same patient, each lesion was evaluated separately.
If a symptom was absent (0 score) before and after
the treatment, that lesion was excluded from
evaluation.WILCOXON’sone-sample test was employed
for statistical analysis.
RESULTS
1) Comparative study between the EPA/DHA-
containing ointment and the placebo (Table 1)
Table 1. Efficacy of EPA/DHA Ointment in Atopic Dermatitis Patients
Symptoms
No.of
patients
evaluateda)
Group
Treatment
period
Symptom
score
Improvement in the degree of
skin symptoms after 4 weeks
of treatmentb) Efficacy
ratec)
Statistical
analysis
(Wilcoxon
one-sample
test)0 1 2 3 －3 －2 －1 0 1 2 3
Erythema 11
EPA/DHA
Pretreatment 0 5 6 0
0 4 5 2 0 0 0
9/11 (81.8%) **
4 weeks 7 4 0 0
Control
Pretreatment 0 7 3 1
0 0 3 6 2 0 0
3/11 (27.3%) NS
4 weeks 3 2 5 1
Papule 12
EPA/DHA
Pretreatment 0 5 7 0
0 4 6 2 0 0 0
10/12(83.3%) **
4 weeks 7 5 0 0
Control
Pretreatment 0 9 2 1
0 0 3 8 1 0 0
3/12 (25.0%) NS
4 weeks 2 6 4 0
Squama 5
EPA/DHA
Pretreatment 0 4 1 0
0 1 4 0 0 0 0
5/5 (100.0%) NSd)
4 weeks 5 0 0 0
Control
Pretreatment 3 1 1 0
0 0 0 2 3 0 0
0/5 (0.0%) NS
4 weeks 0 4 1 0
Itching 10
EPA/DHA
Pretreatment 0 7 2 1
0 2 7 1 0 0 0
9/10 (90.0%) **
4 weeks 7 3 0 0
Control
Pretreatment 1 7 1 1
0 0 4 3 3 0 0
4/10 (40.0%) NS
4 weeks 3 3 4 0
Crust 1
EPA/DHA
Pretreatment 0 1 0 0
0 0 1 0 0 0 0
1/1 (100.0%) NSd)
4 weeks 1 0 0 0
Control
Pretreatment 0 1 0 0
0 0 0 1 0 0 0
0/1 (0.0%) ―
4 weeks 0 1 0 0
Each value indicates the number of patients. ** : p≦0.01, NS : p>0.05 NS = Not Significant
a) The patients with no abnormal skin symptoms pre-and post-treatment were not included.
b) Improvement in the degree of skin symptoms = (symptom score after 4 weeks of treatment)－(symptom score of pretreatment)
[－] represents improvement, [0] represents no change, [+] represents progressive disease.
c) [Total No. of improved cases (score : －3～－1)]/[No. of patients evaluated].
Numbers in parentheses indicate improvement rates (%) VS total No. of patients.
d) Due to the small number of patients treated.
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Therapeutic effects of the test ointment and the
placebo (a hydrophilic-ointment base) were compared
in 12 patients with AD. The study was conducted
in such a way that the test ointment and placebo
were applied to lesions on the left and right arms
or the left and right legs of 12 patients, for 2-7
weeks. The degrees of improvement of skin symp-
toms were compared before and after the treat-
ment. Since 2 of the 7 categories of skin symptoms
were not observed either before or after the treat-
ment, 5 categories were compared. The test oint-
ment showed more than 80% improvement in all 5
categories and the efficacies were significant by
WILCOXON’s one-sample test. On the other hand,
the placebo showed lower rates of improvement
between 0 and 40 % and some of the lesions were
aggravated. No significant difference was detected
before and after the treatment in the placebo
treated lesions.
2) Change in skin symptoms (Table 2)
Change in skin symptoms before and after the
treatment was shown with scores (Mean±S.D.).
Scores after 4 weeks of treatment decreased in all
7 categories compared to the starting time indicat-
ing improvement of skin symptoms. Erythema, papule,
squama, itching and thickening were significantly
decreased as shown by WILCOXON’s one-sample
test. There was no significant difference in the de-
grees of improvement of crust and erosion, prob-
ably due to the small number of eligible subjects.
3) Degree of improvement of skin symptoms in
patients with AD (Table 3)
Distribution of the number of lesions with respect
to the severity of symptoms (0, 1, 2 and 3 points)
showed distinct shifts to lower scores for all 7
categories 4 weeks after the start of treatment
indicating improvement. When the degree of im-
provement of symptoms 4 weeks after the start of
treatment was compared at each site, the highest
improvement was shown in erosion followed by
erythema, papule, thickening, squama, crust and
itching. However, concerning erosion and crust,
the numbers of sites were small and, therefore, no
significant differences were detected by WILCOXON’s
one-sample test.
DISCUSSION
Based on immunohistological study using a patch
test with a mite antigen, Tanaka et al . reported (3)
that histamine, platelet activating factor (PAF),
eosinophilic chemotactic factor (ECF-A) and some
arachidonic acid (AA) metabolites [leukotriene (LT)
B4, LTC4] released from mast cells as well as
eosinophils were involved in the onset of AD.
Fogh et al . (4) revealed that the concentrations of
prostaglandin E2, LTB4 and 12/15 monohydroxy
acid, which are AA metabolites,were increased in
AD lesions and in the skin close to the lesions
compared to the healthy skin of patients with AD
or the skin of healthy subjects. Ruzicka et al .(5)
demonstrated using the suction blister method
that the LTB4 level in lesions of patients with AD
was higher than that in the healthy skin of the
same patients. Thus, AA metabolites in the skin
were suspected to be involved in the mechanism
of the onset of AD.
Table 2 : Improvement of Skin Symptoms by EPA/DHA Ointment
Symptoms
No.of target
lesions
Symptom score (mean±SD)
Statistical analysis
(Wilcoxon one-sample test)Pretreatment After 4 weeks of treatment
Erythema 78 1.63±0.65 0.62±0.76 **
Papule 71 1.69±0.58 0.77±0.72 **
Squama 30 1.60±0.77 0.77±0.73 **
Itching 65 1.88±0.67 1.17±0.84 **
Thickening 11 1.64±0.67 0.45±0.52 *
Crust 16 1.38±1.02 0.63±0.81 NS
Erosion 6 2.00±0.63 0.33±0.52 NS
** : p≦0.01, * : p≦0.05, NS : p>0.05
NS = Not Significant
[Score of skin symptoms : 3 =severe, 2 =moderate, 1 =mild, 0=normal]
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It has been reported that metabolic enzymes
such as lipoxygenase and cyclooxygenase are common
to the AA cascade and EPA cascade and, more-
over, EPA is superior to AA as a substrate for
these common enzymes (6). Therefore, admin-
istration of EPA may competitively inhibit the
progress of the AA cascade through common
enzymes. It has been revealed that in the EPA
cascade, the majority advances to the LTB5 course
and rarely to the LTC5 course (7) and biological
activity of LTB5 is extremely weak compared to
AA-derived LTB4 (8). Furthermore, EPA metabolites
may inhibit the activity of AA metabolites competi-
tively through target cell receptors. Therefore, EPA
administration was considered to inhibit the pro-
duction of AA metabolites as well as the appear-
ance of their effects. In addition DHA, which is an
ω-3 unsaturated fatty acid similar to EPA, was re-
ported to inhibit chemical mediators such as LT
and PAF (9).
Thus, we prepared an EPA and DHA containing
ointment and applied it to patients with refractory
AD. However, two major questions arose concern-
ing the topical use of EPA and DHA. 1) Are EPA
and DHA absorbed percutaneously ? and 2) If EPA
or DHA is absorbed percutaneously, are these
compounds absorbed by target cells ?. Regarding
the first question, the skin of a patient with AD
seems to readily absorb EPA and DHA in the
ointment since it has been reported that unlike
healthy skin, numerous minute apertures and grooves
as well as cellular gaps exist in the skin of patients
with AD due to damage to the skin-barrier system
(10). Concerning the second question, it has been
reported that oral administrations of EPA and
DHA in humans resulted in an increase in the
EPA level and a marked decrease in the AA con-
tent in leukocytes (11), or in an increase in the
EPA content and inhibition of production and re-
lease of AA metabolites including LTB4 (12).
Based on these results, we proposed that an EPA
and DHA-containing ointment would be effective
for patients with AD.
A total of 125 patients with AD visited our
department for treatment with the EPA/DHA-
containing ointment because of poor responses to
Table 3 : Improvement of Skin Symptoms by EPA/DHA Ointment
Symptoms
No.of
symptom
lesions
Treatment
period
Symptom score
Improvement in the degree of skin
symptoms after 4 weeks of treatmenta)
Total No.of
Improved
lesionsb)
Statistical
analysis
(Wilcoxon one-
sample test)0 1 2 3 －3 －2 －1 0 1 2 3
Erythema 78
Pretreatment 0 36 35 7
2 19 40 12 5 0 0 61/78 (78.2%) **
4 weeks 42 25 10 1
Papule 71
Pretreatment 0 26 41 4
2 9 43 15 2 0 0 54/71 (76.1%) **
4 weeks 28 31 12 0
Squama 30
Pretreatment 1 14 11 4
1 5 13 10 1 0 0 19/30 (63.3%) **
4 weeks 12 13 5 0
Itching 65
Pretreatment 2 13 41 9
1 5 30 24 3 2 0 36/65 (55.4%) **
4 weeks 16 24 23 2
Thickening 11
Pretreatment 0 5 5 1
0 6 1 4 0 0 0 7/11 (63.6%) *
4 weeks 6 5 0 0
Crust 16
Pretreatment 3 7 3 3
2 4 3 4 2 0 1 9/16 (56.3%) NS
4 weeks 8 7 0 1
Erosion 6
Pretreatment 0 1 4 1
1 3 1 1 0 0 0 5/6 (83.3%) NS
4 weeks 4 2 0 0
** : p≦0.01, * : p≦0.05, NS : p>0.05
NS = Not Significant
Figures in each column indicate the number of target lesions.
a) Improvement in the degree of skin symptoms = (symptom score after 4 weeks of treatment)－(symptom score of pretreatment)
[－] represents improvement, [0] represents no change, [+] represents progressive disease.
b) [Total No. of improved lesions (score : －3～－1)]/[No. of symptom lesions]
Numbers in parentheses indicate improvement rates (%) VS total No. of lesions.
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conventional treatments. Of these, 64 patients who
were treated with the ointment for more than 4
weeks, were employed to assess the effect of the
ointment. The other 61 patients were excluded
because of exacerbation of AD after cessation of
steroid therapy. The therapeutic effects were evalu-
ated 4 weeks after the start of treatment and sig-
nificant improvement was observed for all skin
symptoms including erythema, papule, squama,
itching, thickening, crust and erosion. The results
of comparative examination between the EPA/
DHA-containing ointment and the ointment base
(Table1) indicated that improvement of symp-
toms by the EPA/DHA-containing ointment was
not due to the ointment base but attributable to
EPA and DHA. Although some cases showed ag-
gravation of symptoms excluding thickening and
erosion, this phenomenon seemed to be derived
from violent scratching. No other adverse reaction
was observed. In this study, only 64 subjects were
examined and the observation period was short (4
weeks). Therefore, further examination is needed
to confirm the efficacy, adverse reactions and the
time of discontinuation of treatment. However, our
findings suggest that the EPA/DHA-containing
ointment for topical use is a promising, novel
therapeutics for AD.
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